Cholangiopathy as part of post-COVID syndrome

Manuel Rojas; Yhojan Rodríguez; Elizabeth Zapata; Juan Carlos Hernández; Juan-Manuel Anaya

doi:10.1016/j.jtauto.2021.100116

Cholangiopathy as part of post-COVID syndrome

J Transl Autoimmun. 2021:4:100116. doi: 10.1016/j.jtauto.2021.100116. Epub 2021 Aug 31.

Authors

Manuel Rojas¹, Yhojan Rodríguez^{1

2}, Elizabeth Zapata¹, Juan Carlos Hernández², Juan-Manuel Anaya^{1

2}

Affiliations

¹ Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia.
² Clinica del Occidente, Bogota, Colombia.

Abstract

Liver compromise in critically ill patients with coronavirus disease 2019 (COVID-19) is common but usually transient and self-limited. However, liver tests on some patients continue to show abnormal results. Herein, a 29-year-old patient with clinical and histological features of cholangiopathy is presented. Despite treatment with ursodeoxycholic acid and cholestyramine, bilirubin and transaminase levels remained elevated. This case report raises awareness of the difficulty of managing this condition in patients with COVID-19.

Keywords: COVID-19; Cholangiopathy; Hepatopathy; Post-COVID syndrome.

Publication types

Case Reports